In order to assess the therapeutic potential of rh Bri2 BRICHOS R221E, we started treatment of AppNL-G-F mice at 9 months, and WT mice were treated in the same way, to enable investigation of potential effects not related to the AD-like pathology (Fig. 1A). The gene discussed is ITM2B; the disease is Alzheimer disease.